GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » Net Change in Cash

Panacea Acquisition II (Panacea Acquisition II) Net Change in Cash : $-0.28 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Panacea Acquisition II's Net Change in Cash for the three months ended in Dec. 2022 was $-0.03 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.28 Mil.

Panacea Acquisition II Net Change in Cash Historical Data

The historical data trend for Panacea Acquisition II's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II Net Change in Cash Chart

Panacea Acquisition II Annual Data
Trend Dec21 Dec22
Net Change in Cash
- -0.28

Panacea Acquisition II Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Change in Cash Get a 7-Day Free Trial - -0.07 -0.15 -0.03 -0.03

Panacea Acquisition II Net Change in Cash Calculation

Panacea Acquisition II's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.283+0+0+0
=-0.28

Panacea Acquisition II's Net Change in Cash for the quarter that ended in Dec. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.031+0+0+0
=-0.03

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Acquisition II Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Acquisition II (Panacea Acquisition II) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » Net Change in Cash
Comparable Companies
PBAX MAQC CFFS TRON CSLM SANB GACQ ALOR BOCN VCKA GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines